Early patient discontinuation from adjuvant endocrine treatment (ET) is multifactorial and complex: Patients must adapt to various challenges and make the best decisions they can within changing contexts over time. Predictive models are needed that can account for the changing influence of multiple factors over time as well as decisional uncertainty due to incomplete data. AtlasTi8 analyses of longitudinal interview data from 82 estrogen receptor-positive (ER+) breast cancer patients generated a model conceptualizing patient-, patient-provider relationship, and treatment-related influences on early discontinuation. Prospective self-report data from validated psychometric measures were discretized and constrained into a decisional logic netw...
An additional 5 years of treatment with adjuvant hormonal therapy, to complete 10 years of medicatio...
Purpose: Despite evidence supporting at least five years of endocrine therapy for early breast cance...
Introduction: Despite evidence of the efficacy of adjuvant endocrine therapy (AET) in reducing the r...
This project proposed that given a basic model of the decisional logic driving stable adherence it m...
Abstract Background Many patients receiving adjuvant endocrine therapy (ET) for breast cancer experi...
Purpose: To inform intervention development, we measured the modifiable determinants of endocrine th...
International audienceThis study aimed to describe adjuvant endocrine therapy adherence trajectories...
International audienceAbstract Background Adjuvant endocrine therapy (AET) is a daily oral medicatio...
International audiencePurpose: Despite the benefits of adjuvant endocrine therapy (AET) for reducing...
Abstract Background Interventions that promote adjuvant endocrine therapy (AET) adherence are critic...
Background:Endocrine therapy adherence remains a barrier to optimal estrogen receptor positive (ER+)...
Predicting an individual's risk of treatment discontinuation is critical for the implementation of p...
PURPOSE: Despite evidence supporting at least five years of endocrine therapy for early breast cance...
An additional 5 years of treatment with adjuvant hormonal therapy, to complete 10 years of medicatio...
Purpose: Despite evidence supporting at least five years of endocrine therapy for early breast cance...
Introduction: Despite evidence of the efficacy of adjuvant endocrine therapy (AET) in reducing the r...
This project proposed that given a basic model of the decisional logic driving stable adherence it m...
Abstract Background Many patients receiving adjuvant endocrine therapy (ET) for breast cancer experi...
Purpose: To inform intervention development, we measured the modifiable determinants of endocrine th...
International audienceThis study aimed to describe adjuvant endocrine therapy adherence trajectories...
International audienceAbstract Background Adjuvant endocrine therapy (AET) is a daily oral medicatio...
International audiencePurpose: Despite the benefits of adjuvant endocrine therapy (AET) for reducing...
Abstract Background Interventions that promote adjuvant endocrine therapy (AET) adherence are critic...
Background:Endocrine therapy adherence remains a barrier to optimal estrogen receptor positive (ER+)...
Predicting an individual's risk of treatment discontinuation is critical for the implementation of p...
PURPOSE: Despite evidence supporting at least five years of endocrine therapy for early breast cance...
An additional 5 years of treatment with adjuvant hormonal therapy, to complete 10 years of medicatio...
Purpose: Despite evidence supporting at least five years of endocrine therapy for early breast cance...
Introduction: Despite evidence of the efficacy of adjuvant endocrine therapy (AET) in reducing the r...